August 9, 2026

Newsletter

The European Post

Policy • Diplomacy • Strategic Insight

LATEST
New EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips AwayEurope Inherits the World’s Aid Bill It Cannot Fully PayAir Passenger Rights Get Their First Overhaul in Two DecadesErasmus Opens a 5 Billion Euro Round for Skills and MobilityCeuta Crisis Pushes the EU Toward Faster Migrant ReturnsBulky Parcels Face a Packaging Crackdown From August 12Can Europe Build Its Drone Wall Before 2030 Arrives?Indonesia’s Trade Deal With Europe Nears Its Final SignatureEurope Leans on Beijing to Keep Climate Talks Alive Before AntalyaNew EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips AwayEurope Inherits the World’s Aid Bill It Cannot Fully PayAir Passenger Rights Get Their First Overhaul in Two DecadesErasmus Opens a 5 Billion Euro Round for Skills and MobilityCeuta Crisis Pushes the EU Toward Faster Migrant ReturnsBulky Parcels Face a Packaging Crackdown From August 12Can Europe Build Its Drone Wall Before 2030 Arrives?Indonesia’s Trade Deal With Europe Nears Its Final SignatureEurope Leans on Beijing to Keep Climate Talks Alive Before Antalya
August 9, 2026

Newsletter

The European Post

Policy • Diplomacy • Strategic Insight

LATEST
New EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips AwayEurope Inherits the World’s Aid Bill It Cannot Fully PayAir Passenger Rights Get Their First Overhaul in Two DecadesErasmus Opens a 5 Billion Euro Round for Skills and MobilityCeuta Crisis Pushes the EU Toward Faster Migrant ReturnsBulky Parcels Face a Packaging Crackdown From August 12Can Europe Build Its Drone Wall Before 2030 Arrives?Indonesia’s Trade Deal With Europe Nears Its Final SignatureEurope Leans on Beijing to Keep Climate Talks Alive Before AntalyaNew EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips AwayEurope Inherits the World’s Aid Bill It Cannot Fully PayAir Passenger Rights Get Their First Overhaul in Two DecadesErasmus Opens a 5 Billion Euro Round for Skills and MobilityCeuta Crisis Pushes the EU Toward Faster Migrant ReturnsBulky Parcels Face a Packaging Crackdown From August 12Can Europe Build Its Drone Wall Before 2030 Arrives?Indonesia’s Trade Deal With Europe Nears Its Final SignatureEurope Leans on Beijing to Keep Climate Talks Alive Before Antalya

When An Anti-Aging Supplement Finally Clears Europe’s Safety Bar

Rudolf Nureyev
Parliament Reporter, Health and Wellbeing

The market for longevity has run far ahead of the regulators meant to police it. For several years a molecule with the unlovely name beta-nicotinamide mononucleotide, sold everywhere as NMN, has been marketed online as a way to slow the cellular wear of ageing, often with claims that outpaced anything a cautious scientist would endorse. The European Union has now taken a decisive step toward putting that trade on a legal footing, after its food-safety authority issued a positive safety opinion clearing the compound for use as a novel food.

The verdict is narrower than the marketing will suggest, and the distinction matters. The authority’s panel on nutrition concluded that NMN is safe for adults to consume in food supplements as a source of niacin, at a daily intake of up to 300 milligrams, while explicitly excluding pregnant and lactating women from that judgement. The panel examined the substance’s identity, how it is manufactured, its composition and its specifications, and found nothing that raised a safety concern. Crucially, this is an opinion about safety, not about whether the dramatic anti-ageing promises attached to the molecule are true.

That gap between safe and effective is the heart of the story. Novel-food authorisation in the bloc asks a deliberately limited question, whether a substance not widely eaten before 1997 can be consumed without harm at the proposed levels. It does not certify that the product does what its sellers claim, and it does not let a supplement maker print health benefits on the label without separate, far harder approval. A consumer reading that NMN has been cleared in Europe should understand they are being told it will not hurt them in the stated dose, not that it will add years to their life.

The procedural mechanics now move from the scientists to the politicians and officials. The favourable opinion feeds into the Commission and member states, who will decide whether to authorise the ingredient formally and on what conditions of use. That step converts a technical assessment into a binding entry on the bloc’s list of permitted novel foods, after which any company meeting the agreed specifications can sell it lawfully across all twenty-seven markets rather than navigating a patchwork of national tolerances.

For a sector that has operated in a grey zone, the clarity cuts both ways. Reputable manufacturers gain a defined, continent-wide route to market and a quality bar that distinguishes them from the unregulated powders sold through obscure websites. But the same rules raise the cost of entry, demanding the kind of dossier on production and bioavailability that a serious applicant must assemble and a fly-by-night seller cannot. One human study comparing how the body absorbs NMN against ordinary nicotinamide supported a clean conversion factor, the sort of evidence that now becomes the price of admission.

There is a consumer-protection logic running underneath all of it. By forcing supplements through a single scientific gate, the bloc replaces a marketplace governed by marketing copy with one governed, at least on safety, by a documented assessment. That will not stop exaggerated claims about reversing ageing, which belong to a different and stricter regime, but it does mean the molecule itself has been examined rather than merely sold. For once, the science is catching up with the supplement aisle, and a product long bought on faith has been asked to show its evidence.

Comments